HNB
PHAT icon

Huntington National Bank’s Phathom Pharmaceuticals PHAT Stock Holding History

Huntington National Bank’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.6K Buy
2,304
+318
+16% +$4.02K ﹤0.01% 1568
2025
Q4 		$32.9K Sell
1,986
-36
-2% -$514 ﹤0.01% 1407
2025
Q3 		$23.8K Buy
2,022
+434
+27% +$4.48K ﹤0.01% 1534
2025
Q2 		$15.2K Buy
1,588
+202
+15% +$1.12K ﹤0.01% 1656
2025
Q1 		$8.69K Sell
1,386
-111
-7% -$674 ﹤0.01% 1801
2024
Q4 		$12.2K Buy
1,497
+26
+2% +$322 ﹤0.01% 1708
2024
Q3 		$26.6K Buy
1,471
+564
+62% +$7.88K ﹤0.01% 1419
2024
Q2 		$9.34K Sell
907
-71
-7% -$731 ﹤0.01% 1718
2024
Q1 		$10.4K Buy
978
+18
+2% +$153 ﹤0.01% 1665
2023
Q4 		$8.77K Sell
960
-91
-9% -$784 ﹤0.01% 1701
2023
Q3 		$10.9K Sell
1,051
-18
-2% -$247 ﹤0.01% 1537
2023
Q2 		$15.3K Buy
1,069
+104
+11% +$1.2K ﹤0.01% 1443
2023
Q1 		$6.89K Buy
965
+40
+4% +$351 ﹤0.01% 1642
2022
Q4 		$10.4K Sell
925
-4
-0.4% -$41 ﹤0.01% 1478
2022
Q3 		$10K Sell
929
-110
-11% -$1.05K ﹤0.01% 1534
2022
Q2 		$9K Buy
1,039
+919
+766% +$9.45K ﹤0.01% 1608
2022
Q1 		$2K Sell
120
-5
-4% -$81 ﹤0.01% 1918
2021
Q4 		$2K Buy
+125
New +$2.94K ﹤0.01% 1903

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Huntington National Bank's PHAT Position: Q1 2026 in Review

Huntington National Bank increased its Phathom Pharmaceuticals (PHAT) stake by 16% in Q1 2026, buying an estimated $4.02K and bringing the position to 2,304 shares worth $25.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1568.

Huntington National Bank first reported a position in PHAT in Q4 2021 and has held it in 18 quarters since. The position peaked at $32.9K in Q4 2025. 174 funds tracked by Wall St. Rank hold PHAT as of Q1 2026.

  • Huntington National Bank held 2,304 shares of Phathom Pharmaceuticals worth $25.6K as of Q1 2026.
  • Huntington National Bank bought 318 Phathom Pharmaceuticals shares in Q1 2026, an estimated $4.02K.
  • Phathom Pharmaceuticals made up ﹤0.01% of Huntington National Bank's portfolio in Q1 2026, its #1568 holding.
  • Huntington National Bank first reported a position in Phathom Pharmaceuticals in Q4 2021 and has held it in 18 quarters since.
  • Huntington National Bank's Phathom Pharmaceuticals position peaked at $32.9K in Q4 2025.
  • 174 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2026.

Based on Huntington National Bank's 13F filing for Q1 2026, filed 15 May 2026.